Novartis India:

SP Tulsian, sptulsian.com is of the view that one can hold Novartis India till Rs 625.

Tulsian told CNBC-TV18, "It is definitely negative for the company, as they have been relying on this cancer drug Glivec for getting that patent, which has not come in, in their favour. They have preferred an appeal to the Supreme Court. So, definitely, this is a negative, but apart from that I want to point out to Mr. Sundaram that if you really see all the multi-national pharma companies whether you talk of Novartis, AstraZeneca , GlaxoSmithKline there are other two-three more companies like Abbot you not finding any upside in this stocks. They are ruling lower than what the Indian or the local biggies are ruling at.

Repco Home Finance:

SP Tulsian, sptulsian.com advises to buy Repco Home Finance around Rs 150-155.

Tulsian told CNBC-TV18, " Repco Home Finance , it was expected that there was a very dull response from the retail space in fact maybe the institutional investor have come to the rescue of this issue. However, I don't find much negative in the stock because nothing was expected.

BHEL:

Sudarshan Sukhani, s2analytics.com advises to buy BHEL on decline. There is probably more upside here.

Sukhani told CNBC-TV18, " Bharat Heavy Electricals (BHEL) is day trading or short-term swing trading opportunity. BHEL has gone down a lot, so a relief rally, a correction, a pullback is expected and that is probably started today. I do not know whether you want to buy it now, but probably on a minor deep it is still a buying opportunity."

Sterlite Ind:

One can buy Sterlite Industries (India) around Rs 80-82, says SP Tulsian, sptulsian.com.

Tulsian told CNBC-TV18, "Since Sterlite Industries (India) is getting merged with Sesa Goa, on a swap ratio of 3:5 i.e. three shares of Sesa Goa will be issued for five shares held in Sterlite Industries."

GoodReturns.in

DISCLAIMER: GoodReturns provides you with information covering shares, futures and options based on broker's reports as stated on various media. Investors are, however, warned that they should NOT take any buy or sell decision based on these views expressed in the article. Investors should consult their own financial and share advisors before taking purchase or sale decisions. GoodReturns does not take any responsibility for any losses incurred by investors who take their cues from the above article.